Orally administered indomethacin acutely reduces cellular prion protein in the small intestine and modestly increases survival of mice exposed to infectious prions

References

• AAguzzi, CSigurdson, MHeikenwaelder. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008;3:11–40.
   PubMed Web of Science ®Google Scholar
• MBeekes, PAMcBride. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies. FEBS J 2007;274:588–605.
   PubMed Web of Science ®Google Scholar
• MHeikenwalder, CFederau, LvBoehmer, PSchwarz, MWagner, NZeller, et al. Germinal center B cells are dispensable in prion transport and neuroinvasion. J Neuroimmunol 2007;192:113–23.
   PubMedGoogle Scholar
• MHeikenwalder, CJulius, AAguzzi. Prions and peripheral nerves: a deadly rendezvous. J Neurosci Res 2007;85:2714–25.
   PubMed Web of Science ®Google Scholar
• NAMabbott, GGMacPherson. Prions and their lethal journey to the brain. Nat Rev Microbiol 2006;4:201–11.
   PubMed Web of Science ®Google Scholar
• IBjarnason, KTakeuchi, RSimpson. NSAIDs: the emperor’s new dogma? Gut 2003;52:1376–8.
   PubMed Web of Science ®Google Scholar
• IBjarnason, GZanelli, TSmith, PProuse, PWilliams, PSmethurst, et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93:480–9.
   PubMed Web of Science ®Google Scholar
• WFFang, ABroughton, EDJacobson. Indomethacin-induced intestinal inflammation. Am J Dig Dis 1977;22:749–60.
   PubMedGoogle Scholar
• OLaneuville, DKBreuer, DLDewitt, THla, CDFunk, WLSmith. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927–34.
   PubMed Web of Science ®Google Scholar
• KCDuggan, MJWalters, JMusee, JMHarp, JRKiefer, JAOates, et al. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem 2010;285:34950–9.
   PubMed Web of Science ®Google Scholar
• ARSallmann. The history of diclofenac. Am J Med 1986;80:29–33.
   PubMed Web of Science ®Google Scholar
• JAMitchell, PAkarasereenont, CThiemermann, RJFlower, JRVane. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693–7.
   PubMed Web of Science ®Google Scholar
• ATanaka, SHase, TMiyazawa, KTakeuchi. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300:754–61.
   PubMed Web of Science ®Google Scholar
• JRVane. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–5.
   PubMedGoogle Scholar
• JLWallace, WMcKnight, BKReuter, NVergnolle. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706–14.
   PubMed Web of Science ®Google Scholar
• ATanaka, SHase, TMiyazawa, ROhno, KTakeuchi. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002;303:1248–54.
   PubMed Web of Science ®Google Scholar
• GRMartin, CMKeenan, KASharkey, FRJirik. Endogenous prion protein attenuates experimentally induced colitis. Am J Pathol 2011;179:2290–301.
   Google Scholar
• CJSigurdson, MHeikenwalder, GManco, MBarthel, PSchwarz, BStecher, et al. Bacterial colitis increases susceptibility to oral prion disease. J Infect Dis 2009;199:243–52.
   Google Scholar
• STsutsu, JNHahn, TAJohnson, ZAli, FRJirik. Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis. Am J Pathol 2008;173:1029–41.
   PubMedGoogle Scholar
• AGDickinson, VMMeikle, HFraser. Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968;78:293–9.
   PubMed Web of Science ®Google Scholar
• CBate, SRutherford, MGravenor, SReid, AWilliams. Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport 2002;13:1933–8.
   PubMedGoogle Scholar
• MFischer, ARulicke, ARaeber, ASailer, MMoser, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 1996;15:1255–64.
   PubMed Web of Science ®Google Scholar
• MGlatzel, AAguzzi. PrPC expression in the peripheral nervous system is a determinant of prion neuroinvasion. J Gen Virol 2000;81:2813–21.
   PubMed Web of Science ®Google Scholar
• EBiasini, JATurnbaugh, UUnterberger, DAHarris. Prion protein at the crossroads of physiology and disease. Trends Neurosci 2012;35:92–103.
   PubMed Web of Science ®Google Scholar
• VHPerry, TANewman, CCunningham. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003;4:103–12.
   PubMed Web of Science ®Google Scholar
• DTWalsh, VHPerry, LMinghetti. Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia 2000;29:392–6.
   PubMedGoogle Scholar
• JIKim, JKJin, EKChoi, DSpinner, RRubenstein, RICarp, et al. Increased expression and localization of cyclooxygenase-2 in astrocytes of scrapie-infected mice. J Neuroimmunol 2007;187:74–82.
   PubMedGoogle Scholar
• LYang, XZhou, JYang, XYin, LHan, DZhao. Aspirin inhibits cytotoxicity of prion peptide PrP106-126 to neuronal cells associated with microglia activation in vitro. J Neuroimmunol 2008;199:10–17.
   PubMedGoogle Scholar
• JKJeong, MHMoon, JWSeol, YJLee, SYPark. Prion peptide-mediated cellular prion protein overexpression and neuronal cell death can be blocked by aspirin treatment. Int J Mol Med 2011;27:689–93.
   PubMedGoogle Scholar
• MOtto, LCepek, PRatzka, SDoehlinger, IBoekhoff, JWiltfang, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 2004;62:714–18.
   PubMed Web of Science ®Google Scholar
• IBone, LBelton, ASWalker, JDarbyshire. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008;15:458–64.
   PubMed Web of Science ®Google Scholar
• IRWhittle, RSKnight, RGWill. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir (Wien) 2006;148:677–9; discussion 679.
   PubMed Web of Science ®Google Scholar
• LManuelidis, WFritch, IZaitsev. Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet 1998;352:456.
   PubMed Web of Science ®Google Scholar
• LMinghetti, AGreco, FCardone, MPuopolo, ALadogana, SAlmonti, et al. Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 2000;59:866–71.
   PubMedGoogle Scholar
• LMinghetti, FCardone, AGreco, MPuopolo, GLevi, AJGreen, et al. Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology 2002;58:127–9.
   PubMedGoogle Scholar
• DKontoyiannis, MPasparakis, TTPizarro, FCominelli, GKollias. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387–98.
   PubMed Web of Science ®Google Scholar
• KTakeuchi, ATanaka, SKato, KAmagase, HSatoh. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 2010;411:459–66.
   PubMed Web of Science ®Google Scholar
• AYokota, MTaniguchi, YTakahira, ATanaka, KTakeuchi. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther 2005;314:302–9.
   PubMedGoogle Scholar
• BIGustafsson, DSDelbro. Motor effects of indomethacin, morphine or vagal nerve stimulation on the feline small intestine in vivo. Eur J Pharmacol 1993;230:1–8.
   PubMed Web of Science ®Google Scholar
• RALevine, EHSchwartzel. Effect of indomethacin on basal and histamine stimulated human gastric acid secretion. Gut 1984;25:718–22.
   PubMed Web of Science ®Google Scholar
• TCMartinsen, SLBenestad, TMoldal, HLWaldum. Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scand J Gastroenterol 2011;46:1418–22.
   PubMed Web of Science ®Google Scholar
• TCMartinsen, DMTaylor, RJohnsen, HLWaldum. Gastric acidity protects mice against prion infection? Scand J Gastroenterol 2002;37:497–500.
   PubMed Web of Science ®Google Scholar